Is essential thrombocythemia a terminal illness?
Apr 24, 2023
Source: Cainiu Health
Dr. Zhang Heyang
Introduction
Essential thrombocythemia is generally not a terminal illness, although in rare cases it may transform into leukemia, potentially endangering life, thus requiring active treatment. When detected early, essential thrombocythemia can be effectively managed under a doctor's guidance with medications such as enteric-coated aspirin tablets, ligustrazine oral solution, and hydroxyurea tablets. This approach usually achieves good therapeutic outcomes and effectively controls disease progression.
Essential thrombocythemia is generally not a terminal illness. In very rare cases, it may transform into leukemia, which could be life-threatening, so active treatment is necessary. The detailed analysis is as follows:
Essential thrombocythemia is a chronic myeloproliferative disorder characterized primarily by abnormal proliferation of bone marrow megakaryocytes and persistently elevated platelet counts, along with impaired platelet function. Patients often experience recurrent spontaneous mucocutaneous bleeding, thrombosis, and splenomegaly. In the early stages, essential thrombocythemia typically presents no symptoms and progresses slowly, causing no harm to health. Therefore, it is not considered a terminal disease. However, if left untreated and symptoms worsen, a small number of patients may progress to leukemia, posing a threat to life, underscoring the importance of early intervention.
In addition, when essential thrombocythemia is detected early, it can be effectively managed under a doctor's guidance using medications such as enteric-coated aspirin tablets, ligustrazine oral solution, and hydroxyurea tablets. These treatments usually achieve favorable outcomes and effectively control disease progression.
